openPR Logo
Press release

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market: Growth Dynamics| by key vendors Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd.and others.

06-13-2019 12:52 PM CET | Health & Medicine

Press release from: Future Market Insights

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market: Growth Dynamics| by key vendors Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd.and others.

Cancer is a leading cause of death worldwide, accounting nearly 1.4 million new cases in 2012. The most common cause of cancer is lung cancer accounting about 1.59 million deaths, globally. Other prominent cancers are liver cancer, breast cancer, stomach cancer, esophageal and stomach cancer. In 2012, nearly 8.2 million deaths occurred from aforementioned indication, globally. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, precision medicine and stem cell transplantation. The most common treatment for cancer is chemotherapy; it uses drugs to kill cancer cells that cause pain and other problems. Chemotherapy may be used in combination with other cancer treatments. Chemotherapy given before surgery and radiation therapy to make the tumor cell smaller is known as neo-adjuvant chemotherapy and chemotherapy given after treatment with surgery or radiation therapy is known as adjuvant chemotherapy.

Request to Sample of Report @ www.futuremarketinsights.com/reports/sample/rep-gb-2957

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Key Players

Some of the key players in global Chemotherapy-induced Nausea and Vomiting Therapeutics Market are GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceuticals, Heron Therapeutics, Inc., F. Hoffmann-La Roche AG, Tesaro, Inc., Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd.and others.

Chemotherapy, not only kills the cancer cells but also attacks healthy cells that leads to side effects such as fatigue, hair loss, nausea, and vomiting. Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the most serious side effects that is taken into account. Chemotherapy-induced nausea and vomiting are classified as acute, that occurs within 24 hours of the treatment; anticipatory, that is triggered due to some exposed stimuli; other are refractory; delayed and breakthrough. Incidence, timing, and intensity of chemotherapy-induced nausea and vomiting vary on chemotherapeutic agents and patient factors. CINV occurs in about 80% of patients and has a severe impact on patient’s life.

Antiemetics are less effective in controlling nausea and vomiting because the intensity is high than actual vomiting. Proper antiemetics can prevent CINV in about 60%-70% of patients. Nowadays due to research and development in the field of cancer therapeutics, many treatment options are available to manage and treat CINV by addressing antiemetic property to an individual patient. Conventionally Chemotherapy-Induced Nausea and Vomiting was managed with dopamine receptor antagonists only. Currently, multiple options are available that is used in the prevention and management of CINV.

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Drivers and Restrains

According to Word Health Organization, it is estimated that by 2030, about 23.6 million new cases of cancer will prevail worldwide. Agents are available for the treatment of chemotherapy-induced nausea and vomiting NK1 receptor antagonists, corticosteroids, -HT3 receptor antagonists and others. Governmental guidelines from American Society of Clinical Oncology and National Comprehensive Cancer Network (NCCN /ASCO) are providing help to healthcare professionals to manage antiemetic regimens for patients. Intense research and development in cancer therapeutics, the rise in the incidence of cancer cases, increased preference toward chemotherapy for the treatment of cancer and the use of chemotherapy in combination with other cancer treatment are anticipated to fuel the growth of chemotherapy-induced nausea and vomiting. The decline in the use of chemotherapy drugs in future can decline the growth of chemotherapy-induces nausea and vomiting therapeutics market.

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Segmentation

The global chemotherapy-induced nausea and vomiting therapeutics market has been classified by therapy type, route of administration, distribution channel, and geography.

Based on Therapy Type, the Chemotherapy-induced Nausea and Vomiting Therapeutics Market is divided into following:

Dopamine Antagonists

Serotonin Receptor Antagonists

Corticosteroids

Benzodiazepines

Neurokinin NK1 receptor antagonist

Based on the Route of Administration, the global Chemotherapy-induced Nausea and Vomiting Therapeutics Market is divided into following:

Oral

Intravenous

Based on the Distribution Channel, the global Chemotherapy-induced Nausea, and Vomiting Therapeutics Market is divided into following:

Hospital Pharmacy

Drug Stores

Retail Pharmacy

E-commerce

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Overview

Based on the therapy type, the global chemotherapy-induced nausea and vomiting therapeutics market is segmented into dopamine antagonists, serotonin receptor antagonists, corticosteroids, benzodiazepines, and neurokinin NK1 receptor antagonist. Serotonin receptor antagonists are said to account the major share in the chemotherapy-induced nausea and vomiting therapeutics market as it is most commonly used and is effective. It blocks the binding of serotonin to its receptor, thus stopping the signal to the brain. By route of administration the chemotherapy-induced nausea and vomiting therapeutics market is segmented into oral and intravenous administration. Based on the distribution channel the CINV market is segmented into hospital pharmacy, drug store, retail pharmacy, and e-commerce. The rise in cancer patient population, funding by the governmental bodies, focus on acquisition and merger by various key manufacturers is attributed towards the growth of chemotherapy-induced nausea and vomiting therapeutics.

Request Report for TOC @ www.futuremarketinsights.com/toc/rep-gb-2957

Chemotherapy-induced Nausea and Vomiting Therapeutics Market: Regional Overview

Region-wise, the global Chemotherapy-induced Nausea and Vomiting Therapeutics Market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. More than 70% of world's cancer death occurs in Africa, Asia, and South America. Around 33% of cancer cases worldwide are due to smoke and tobacco. Along with expansion in the emerging markets, and a greater focus on early diagnosis, screening, monitoring and clinical development of CINV drugs have been the major strategies adopted by major players in the global chemotherapy-induced nausea and vomiting therapeutics market.

U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chemotherapy-Induced Nausea And Vomiting Therapeutics Market: Growth Dynamics| by key vendors Acacia Pharma, Baxter international Inc., Lee's Pharmaceutical Holdings, Mundipharma International limited, Kyowa Hakko Kirin Co., Ltd.and others. here

News-ID: 1774367 • Views: 87

More Releases from Future Market Insights

Video on Demand Service Market- The Animation segment is Expected to Grow at a h …
A recent market report published by Future Market Insights titled “Video on Demand Service Market: Global Industry Analysis (2014-2016) & Opportunity Assessment (2017-2027)” presents detailed insights and a revised forecast of the global video on demand service market for the period 2017 – 2027. According to the report, the global market for video on demand service was valued at around US$ 53 Mn in 2016, and is expected to register
Smart Home Devices Market- Technological Advancements to Underscore Lucrative Gr …
A new report published by Future Market Insights titled ‘Smart Home Devices Market: Global Industry Analysis (2012 – 2016) and Opportunity Assessment (2017 – 2027)’ studies the performance of the global smart home devices market over a 10 year assessment period from 2017 to 2027. The report presents the value forecast of the global smart home devices market and provides key insights on the factors driving market growth as well
Automatic Coffee Machines Market- Technological Advancements to Underscore Lucra …
Growing need to offer quick services in cafés and restaurants has led to surge in demand for automatic coffee machines globally. In addition, surge in demand for technologically enhanced automatic coffee machine is projected to impact the global market growth of automatic coffee positively. Future Market Insights states that the global market of automatic coffee machine is projected to register a CAGR of 6.0% over the forecast period, 2017-2026. Factors Fuelling
Version Control Systems Market- Competitive Analysis by Leading Industry Players …
A new report published by Future Market Insights titled “Version Control Systems Market: Global Industry Analysis (2012–2016) and Opportunity Assessment (2017–2027)” tracks the details of the global market for a projected period of 10 years, i.e. between 2017 and 2027. According to this report, global sales of version control systems is estimated to be valued at US$ 326.1 Mn in 2017 and is estimated to reach US$ 971.8 Mn by

All 60883 Releases


More Releases for Chemotherapy

Chemotherapy Induced Neutropenia Market Report by MarketResearchReports.biz
"The Latest Research Report Chemotherapy Induced Neutropenia-Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2018, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness,
Nano Chemotherapy Market Nano Chemotherapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine 1.1 Overview 1.2 Nano Chemotherapeutics with Pharmaceutical Potential Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations 2.1 Limitations of Conventional Chemotherapy 2.2 Nanotechnology in Cancer Targeting 2.2.1 Active Targeting 2.2.2 Passive Targeting 2.2.3 pH Dependent Drug Delivery Through Nanoparticles Role
Global Chemotherapy Pumps Sales Market Report 2017
This report studies sales (consumption) of Chemotherapy Pumps in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Bayer Healthcare Becton & Dickson GE Medical BMS Celsus Laboratories Johnson and Johnson CME Medical Codman and Shurtleff Takeda Novartis Covidien D. Medical Industries Danone Nutricia Debiotech Alcor Scientific Alkermes Allied Medical Generex Biotechnology Corporation Trivitron Valeritas Vectura Vishal Surgical WalkMed Inc Zevex Hospira To Get Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=984092&type=E Market Segment by Regions,
Chemotherapy Pump Market Research Report 2017
Global Chemotherapy Pump Industry 2021 Market Research Report analyzed the current state in the definitions, classifications, applications and industry chain structure. The report also focuses on the development trends as well as history, competitive landscape analysis, and key regions etc in the international markets. Global Chemotherapy Pump Industry 2021 Market Research Report is a professionally prepared report comprising of in-depth information as well as knowledge which is helpful to the new
09-22-2016 | Health & Medicine
bmr
2020 Chemotherapy Market Globally analysis
“Global Chemotherapy Market Research Report 2016” Order This Report by calling BigMarketResearch.com at +1-971-202-1575 Notes: Production, means the output of Chemotherapy Revenue, means the sales value of Chemotherapy This report studies Chemotherapy in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering Pfizer Inc. (USA) Abbott Laboratories (USA) Genentech Inc. (USA) GlaxoSmithKline Plc (UK) Immunomedics, Inc. (USA) Indevus
Chemotherapy without almost any side effects
Chemotherapy without almost any side effects using insulin potentiated therapy (IPT) Relief for cancer patients: Insulin Potentiated Therapy makes it possible to have more gentle chemotherapy without almost any side effects. By combining chemotherapeutics with insulin, only one-fifth of the debilitating drugs are necessary. "Chemotherapy is the routine for treating cancer in the orthodox school of medicine," says Dr. med. Peter wolf. "But chemotherapy has three fundamental disadvantages: Chemotherapeutics do not distinguish